SAN DIEGO, March 22 /PRNewswire-FirstCall/ -- Protein Polymer
Technologies, Inc. (OTC Bulletin Board: PPTI) announced today the election of
William N. Plamondon III, President and CEO of R.I. Heller & Co., to its Board
of Directors.
    "Bill Plamondon has been an advisor to PPTI for the last six months.  With
his impressive business management career having served as CEO for both public
and private companies, Bill brings PPTI a wealth of business knowledge," said
J. Thomas Parmeter, PPTI Chairman and CEO.  "His financial expertise and
organizational structuring experience will add great value to PPTI."
    Plamondon is currently President and CEO of R.I. Heller & Co., LLC, an
interim management firm that provides financial and organizational
restructuring, growth strategies, and mergers and acquisition execution to
companies experiencing change and challenges.
    Previously he served as President and CEO of Budget Rent a Car, a
$2.6 billion dollar public company, capping off 19 years with the company,
leaving when Ford sold the company in 1997.  Plamondon also served as
President and CEO for ANC Rental Corporation, a $3.5 billion international
company with 3,200 locations in 83 countries.
    Plamondon serves on the boards of private and public companies, as well as
non-profit organizations.  He was a founding member of the National Tourism
Organization and formerly served on the Board of American Car Rental
Association and the International Franchise Association.  He currently serves
on the Board of Directors for Tribridge, and the Board of Trustees of North
Central College.  He is a seven-year member of the Executive Advisory
Committee for Give Kids the World, and is an active member of the American
Bankruptcy Institute and the Turnaround Management Association.

    Protein Polymer Technologies, Inc., is a San Diego-based company focused
on developing products to improve medical and surgical outcomes.  From its
inception in 1988, PPTI has been a pioneer in protein design and synthesis,
creating an extensive portfolio of proprietary biomaterials for use in the
development of bioactive devices.  These genetically engineered biomaterials
are high molecular weight proteins, processed into products with physical and
biological characteristics tailored to specific clinical performance
requirements.  Targeted products include urethral bulking agents for the
treatment of stress urinary incontinence, dermal augmentation products for
cosmetic and reconstructive surgery, surgical adhesives and sealants,
scaffolds for wound healing and tissue engineering, and depots for local drug
delivery.  To date, PPTI has been issued twenty-six U.S. Patents on its core
technology with corresponding issued and pending patents in key international
markets.

    This press release contains forward-looking statements that are based on
management's views and expectations.  Actual results could differ materially
from those expressed here; further, the Company is not obligated to comment
specifically on those differences.  Risks associated with the Company's
activities include raising adequate capital to continue operations, scientific
and clinical product development uncertainties, competitive products and
approaches, continuing collaborative partnership interest and funding,
regulatory testing and approvals, and manufacturing scale-up.  The reader is
encouraged to refer to the Company's 2003 Annual Report on Form 10-KSB, the
Company's quarterly reports on Form 10QSB for the periods ended March 31,
2004, June 30, 2004 and September 30, 2004, and other recent filings with the
Securities and Exchange Commission, copies of which are available from the
Company, to further ascertain the risks associated with the above statements.

Link to this page: